Evidence for genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 2, 1996, Pages 105-110

  Bioque, Gloria ^a   Bouma, Gerd ^a   Crusius, J Bart A ^a   Koutroubakis, Ioannis ^a   Kostense, Pieter J ^a   Meuwissen, Stephan G M ^a   Peña, A Salvador ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HLA DR2; Inflammatory bowel disease; Interleukin 1 receptor antagonist; Perinuclear anti neutrophil cytoplasmic antibodies

Indexed keywords

ETHIDIUM BROMIDE; HLA DR2 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOT HYBRIDIZATION; EXON; FEMALE; GEL ELECTROPHORESIS; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC PREDISPOSITION; GENOTYPE; HLA TYPING; HUMAN; IMMUNOFLUORESCENCE; INTRON; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0029965797     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199602000-00003     Document Type: Article

References (39)

1. Shanahan F, Targan SR: Mechanisms of tissue injury in inflammatory bowel disease. In Current topics in gastroenterology. Inflammatory Bowel Disease. Edited by MacDermott RP, Stenson WF. New York: Elsevier; 1992:77-94.
2. Schreiber S, Raedler A, Stenson Wf, Macdermott RP: The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am 1992, 21:451-502.
3. Satsangi J, Jewell DP, Rosenberg WMC, Bell JI: Genetics of inflammatory bowel disease. Cur 1994, 35:696-700.
4. Yang H, Rotter JI. The genetics of inflammatory bowel disease. In Inflammatory bowel disease: from the bench to bedside. Edited by Targan S, Shanahan F. Baltimore: Williams and Wilkins; 1994:32-64.
5. Shohat T, Vadheim CM, Rotter JI: The genetics of inflammatory bowel disease. In Inflammatory bowel disease: a physicians guide. New York: Igaku-Shoin; 1992:53-86.
6. Toyoda H, Wang S-J, Yang HY, Redford A, Magalong D, Tyan D, et al.: Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993, 104:741-748.
7. Dinarello CA: Biology of interleukin 1. Faseb J 1988, 2:108-115.
8. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK: There is more than one interleukin 1. Immunol Today 1986, 7:430-436.
9. Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD, Wasserman MA: Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989, 97:326-337.
10. Cominelli F, Nast CC, Clark BD, Schlinder R, Llerena R, Eysselein VE, et al.: Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990, 86:972-980.
11. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D: Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 1990, 31:686-689.
12. Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S: Cytokine production in patients with inflammatory bowel disease. Gut 1992, 33:933-937.
13. Mahida YR, Wu K, Jewell DP: Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989, 30:835-838.
14. Cominelli F, Nast CC, Duchini A, Lee M: Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992, 103:65-71.
15. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F: Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994, 94:449-453.
16. Isaacs KL, Sartor RB, Haskill S: Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992, 103:1587-1595.
17. Cominelli F, Fiocchi C, Eisenberg SP, Bortolami M: Imbalance of IL-1 and IL-1 receptor antagonist in the intestinal mucosa of Crohn's disease and ulcerative colitis patients. Gastroenterology 1992, 102:A609.
18. Cominelli F, Kam L, Casini-Raggi V, Jin Y, Pizarro TT: Specific mucosal imbalance of IL-1 and IL-1 receptor antagonist (IL-1ra) in IBD: a potential mechanism of chronic inflammation. Gastroenterology 1994, 106:A667.
19. Tarlow JK, Blakemore AIF, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al.: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993, 91:403-404.
20. Mansfield JC, Holden H, Tarlow JK, di Giovine FS, McDowell TL, Wilson AG, et al.: Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994, 106:637-642.
21. Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24 (suppl 170):2-6.
22. Gregersen PK, Todd JA, Erlich HA, Long E, Servenius B, Choi E, et al.: Histocompatibility Testing 1987. In Immunobiology of HLA; vol 1. New York: Spring Verlag; 1989:1207.
23. Verduyn W, Doxiadis IIN, Anholts J, Drabbels JJ, Naipal AMIH, D'Amaro J, et al.: Biotinylated DRB sequences-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in Eurotransplant. Hum Immunol 1993, 37:59-67.
24. Mehra Nk, Verduyn W, Taneja V, Drabbels J, Singh SPN, Giphart MJ: Analysis of HLA-DR2-associated polymorphisms by oligonucleolide hybridization in an Asian Indian population. Hum Immunol 1991, 32:246-253.
25. Wiik A: Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS 1989, 97:12-13.
26. Mehta C, Patel N: In StatXact-Turbo. Statistical Software for Exact Nonparametric Inference. User Manual. Cambridge MA: CYTEL Software Corporation; 1992.
27. Peña AS, Crusius JBA, Oudkerk Pool M, Gracia Casanova M, Pals G, Meuwissen SGM, et al.: Genetics and epidemiology may contribute to understanding the pathogenesis of IBD - a new approach is now indicated. Can J Gastroenterol 1993, 7:71-75.
28. Arend WP, Dayer JM: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33:305-315.
29. Rambaldi A, Torcia M, Bettoni S, Vannier E, Barbui T, Shaw AR, et al.: Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 1991, 78:3248-3253.
30. Hammerberg C, Arend WP, Fisher GJ, Chan LS, Berger AE, Haskill JS, et al.: Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992, 90:571-583.
31. Clay FE, Cork MJ, Tarlow JK, Blakemore AIF, Harrington CI, Lewis F, Duff GW: Interleukin-1-receptor antagonist gene polymorphism association with lichen sclerosus. Human Genet 1994, 94:407-410.
32. Dinarello CA, Wolff SM: The role of interleukin-1 in disease. N Engl J Med 1993, 328:106-113.
33. Steinkasserer A, Koelble K, Sim RB: Length variation within intron 2 of the human IL-1 receptor antagonist protein gene (IL-1RN). Nucleic Acids Res 1991, 19:5095.
34. Tarlow JK, Blakemore AIF, Cork MJ, Messenger A, McDonagh A, Bleehen SS, et al.: Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and chronic inflammatory diseases. Lymphokine and Cytokine Res 1993, 12:A181.
35. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW: Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994, 37:1380-1385.
36. Pociot F, Nerup J: The IL-1 receptor antagonist. A new susceptibility marker in familial insulin-dependent diabetes (IDDM)?. Lymphokine Cytokine Res 1993, 12:A201.
37. Mandrup-Poulsen T, Pociot F, Mølvig J, Shapiro L, Nilsson P, Emdal T, et al.: Monokine antagonism is reduced in patients with IDDM. Diabetes 1994, 43:1242-1247.
38. Oudkerk Pool M, Ellerbroek PM, Ridwan BU, Goldschmeding R, von Blomberg BME, Peña AS, et al.: Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993, 34:46-50.
39. Oudkerk Pool M, Bouma G, Crusius JBA, Naipal AMIH, Kolkman JJ, Meuwissen SGM, et al.: Evidence for genetic heterogeneity in IBD. HLA class II and pANCA in ulcerative colitis and Crohn's disease. Submitted.